Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
David Young is Pres. Research & Development at Processa Pharmaceuticals. OQRO lists 10 transactions filed with the SEC under this name, the latest on Jul 2, 2026, each linked to the official Form 4.
Pres. Research & Development
Disclosures on record
10
Companies involved
1
8 buys, median −26.3 pts vs S&P 500, beat it 0 of 8 times.
Average −29.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jan 29, 2025 to Jul 2, 2026, measured from the first close after the filing. Past results, not a forecast.
8 purchases disclosed; 0% of the 8 measured at 90 days finished ahead of the index. $1,000 placed after each of the 7 purchases disclosed since 2025-11-16 would be worth $5.2K today ($7K put in); the same in the S&P 500 (SPY): $7.3K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Processa PharmaceuticalsPCSA
10 disclosures · Jan 2025 – Jul 2026 · 8 bought
Jun 30, 2026Bought~$4.9Kdisclosed Jul 2
DetailsOfficial recordJun 15, 2026Bought~$4.6Kdisclosed Jun 17
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
May 29, 2026Bought~$4.6Kdisclosed Jun 2
DetailsOfficial recordMay 15, 2026Bought~$4.6Kdisclosed May 20
DetailsOfficial recordApr 30, 2026Bought~$4.6Kdisclosed May 2
DetailsOfficial recordApr 15, 2026Bought~$4.6Kdisclosed Apr 18
DetailsOfficial recordMar 31, 2026Bought~$4.6Kdisclosed Apr 2
DetailsOfficial recordJan 1, 202649disclosed Feb 5
DetailsOfficial recordJan 1, 202649disclosed Feb 5
DetailsOfficial recordJan 27, 2025Bought~$99Kdisclosed Jan 29
DetailsOfficial recordAs of the latest filing on , David Young reported holding 21,729 shares of Processa Pharmaceuticals (PCSA), worth about $37K at the last close of $2 (Nov 16, 2026). In the last 12 months, David Young bought $32K in 7 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Processa Pharmaceuticals PCSA | 21,729 | 22K direct | $2 | $37K | Jun 30, 2026 |
Is this David Young’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
David Young bought shares on the open market in 2021, 2023, 2024, 2025 and 2026.
David Young reported 16 open-market purchases and 0 sales since 2021; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $32K7×7 trades | — |
| 2025 | $99K1×1 trade | — |
| 2024 | $102K2×2 trades | — |
| 2023 | $72K5×5 trades | — |
| 2021 | $77K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
David Young reported 16 open-market purchases and 0 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Jun 30, 2026, David Young reported holding 21,729 shares of Processa Pharmaceuticals (PCSA). At the last close of $2 on Nov 16, 2026, that is about $37K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, David Young reported 7 open-market purchases worth $32K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
David Young bought shares on the open market in 2021, 2023, 2024, 2025 and 2026.
In SEC filings since 2021: the latest open-market purchase is from 2026; no open-market sale is on record.
Processa Pharmaceuticals (PCSA), from 2021 to 2026: 16 purchases and 0 sales.